Loading publications…
The last 5 uploaded publications
Abstract 2223: Phase I clinical trial combining camu camu prebiotic enriched with castalagin modulates bile acids and metabolites in combination with cancer immunotherapy in patients with treatment-naïve lung cancer and PD-1 refractory melanoma (NCT05303493)
Jade Maillou, Reilly Pidgeon, Diogjena Katerina Prifti, Meriem Messaoudene, Sreya Duttagupta, Myriam Benlaïfaoui, Yongjia Hu, A. A. Filin, Mayra Ponce, Wiam Belkaïd, Julie Malo, Guido Guido Kroemer, Sylvère Durand, Olivier Barbier, Nathalie Daaboul, Normand Blais, Mustapha Thefe, Marie Florescu, Rahima Jamal, Wilson H. Miller, Antoine Desîlets, Bastien Castagner, Arielle Elkrief, Bertrand Routy (2025). Abstract 2223: Phase I clinical trial combining camu camu prebiotic enriched with castalagin modulates bile acids and metabolites in combination with cancer immunotherapy in patients with treatment-naïve lung cancer and PD-1 refractory melanoma (NCT05303493). , 85(8_Supplement_1), DOI: https://doi.org/10.1158/1538-7445.am2025-2223.
Article72 days agoFigure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221276.
Preprint61 days agoTable 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Table 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221270.
Preprint61 days agoTable 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Table 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221267.
Preprint61 days agoFigure 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto, Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli (2025). Figure 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221279.
Preprint61 days ago